2024
OR24-01 Time to Sperm Suppression With Daily Transdermal Use of Nestorone and Testosterone Combination Gel for Male Contraception Is Faster Than Expected
Gross D, Wang C, Page S, Sitruk-Ware R, Creinin M, Anderson R, Edelman A, Turok D, Kinuthia J, Vinay J, Barnhart K, Danielsson K, Mhlanga F, Fitzgerald C, Meriggiola C, Archer D, Lazorwitz A, Amory J, Swerdloff R, Bremner W, Lee M, Kroopnick J, Blithe D. OR24-01 Time to Sperm Suppression With Daily Transdermal Use of Nestorone and Testosterone Combination Gel for Male Contraception Is Faster Than Expected. Journal Of The Endocrine Society 2024, 8: bvae163.2435. PMCID: PMC12047133, DOI: 10.1210/jendso/bvae163.2435.Peer-Reviewed Original ResearchSperm suppressionWeek 8Male contraceptionCombination gelPhase IIb clinical trialDaily self-administrationTime to suppressionWeeks of treatmentFollow-up visitWeek 5Reversible male contraceptive methodsSperm concentration assessmentMale contraceptive methodsDaily skin applicationsSpermatogenic suppressionContraceptive efficacyHormone regimensEffective contraceptionHormonal agentsSelf-AdministrationInitial treatmentSegesterone acetateCo-administrationGel applicationTransdermal use
2020
Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
Borba M, Val F, Sampaio V, Alexandre M, Melo G, Brito M, Mourão M, Brito-Sousa J, Baía-da-Silva D, Guerra M, Hajjar L, Pinto R, Balieiro A, Pacheco A, Santos J, Naveca F, Xavier M, Siqueira A, Schwarzbold A, Croda J, Nogueira M, Romero G, Bassat Q, Fontes C, Albuquerque B, Daniel-Ribeiro C, Monteiro W, Lacerda M. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. JAMA Network Open 2020, 3: e208857. PMID: 32330277, PMCID: PMC12124691, DOI: 10.1001/jamanetworkopen.2020.8857.Peer-Reviewed Original ResearchConceptsHigh dosage groupSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionAcute respiratory syndrome coronavirus 2 infectionLow dosage groupSyndrome coronavirus 2 infectionCoronavirus 2 infectionChloroquine diphosphateDay 13COVID-19Phase IIb clinical trialNonsevere COVID-19Secondary end pointsSevere COVID-19High-dose groupSpecific antiviral therapyTertiary care facilityIIb clinical trialCoronavirus disease 2019More heart diseaseParticipants' clinical statusAdjunctive therapyAdult patientsIll patientsPrimary outcomeAntiviral therapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply